0.00
전일 마감가:
$0.0941
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$5.67M
수익:
$7.10M
순이익/손실:
$-31.59M
주가수익비율:
0.00
EPS:
-2.61
순현금흐름:
$-26.75M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
Palatin Technologies Inc. Stock (PTN) Company Profile
명칭
Palatin Technologies Inc.
전화
609-495-2200
주소
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
PTN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PTN
Palatin Technologies Inc.
|
0.00 | 5.67M | 7.10M | -31.59M | -26.75M | -2.61 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2015-06-05 | 재확인 | Canaccord Genuity | Buy |
2015-01-12 | 재확인 | ROTH Capital | Buy |
2012-05-23 | 개시 | Noble Financial | Buy |
2007-01-23 | 개시 | Next Generation | Buy |
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin Technologies Stockholders Approve Key Governance Changes - TipRanks
Palatin Technologies shareholders approve reverse stock split and board elections - Investing.com
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - ADVFN Brasil
Palatin Technologies reports efficacy of PL-7737 in obesity model - BioWorld MedTech
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity - The Malaysian Reserve
Palatin announces positive preclinical efficacy data for oral MC4R agonist PL7737 in animal model of obesity - MarketScreener
Breakthrough Oral Weight Loss Drug Achieves 15% Reduction When Combined with Tirzepatide in Just 4 Days - Stock Titan
Palatin Technologies receives NYSE American delisting notice, appeals decision By Investing.com - Investing.com Nigeria
Palatin Technologies receives NYSE American delisting notice, appeals decision - Investing.com Australia
Palatin Technologies Announces Closing of Reduced Public Offering (PR Newswire) - Aktiellt
Palatin Technologies Raises $340K in Private Placement - TipRanks
Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus
Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus
Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN
Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq
Palatin's New Obesity Drug Shows 4.4% Weight Loss When Combined With Popular GLP-1 Treatment - Stock Titan
Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World
Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com UK
Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India
Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq
Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus
Two new option listings and two option delistings on May 9th - TipRanks
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus
Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN
Palatin Technologies Announces Closing of Reduced Public Offering - Morningstar
Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve
Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus
PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Nigeria
Palatin Technologies Inc. (PTN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):